Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

alfa wassermann s.p.a. - Сулодексид - 250 lsu capsules, soft

Búlgaría - búlgarska - Изпълнителна агенция по лекарствата

alfa wassermann s.p.a. - Сулодексид - 600 lsu/2 ml solution for injection

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

vétoquinol sa - emodepside, praziquantel, tigolaner - Антгельминтики, - Котки - for cats with, or at risk from, mixed parasitic infestations. the veterinary medicinal product is exclusively indicated when ectoparasites, cestodes and nematodes are targeted at the same time.

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

alfasigma s.p.a. - piperaquine tetraphosphate, artenimol - малария - антипротозойни - eurartesim е показан за лечение на неусложнена малария plasmodium falciparum при възрастни, деца и бебета на 6 месеца и повече и с тегло 5 kg или повече. Трябва да се вземат предвид официалните препоръки за правилното използване на малария агенти.

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

laboratorios farmacéuticos rovi, s.a. - Рисперидон - шизофрения - психолептици - treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone.

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

ceva santé animale - pyriproxyfen, dinotefuran - Антипаразитни препарати, инсектициди и репеленти, други ectoparasiticides за външно приложение, pyriproxyfen, комбинации - Котки - Лечение и профилактика на инвазия на бълхи (ctenocephalides Фелиз) на котки. Едно приложение предотвратява бълха паразитози в рамките на един месец. Той също така пречи на размножаването на бълхите, предотвратява появата на бълхите в околната среда на котката, на 3 месеца.

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - Антинеопластични средства - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

janssen-cilag international nv - ciltacabtagene autoleucel - Множествена миелома - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

kite pharma eu b.v. - autologous peripheral blood t cells cd4 and cd8 selected and cd3 and cd28 activated transduced with retroviral vector expressing anti-cd19 cd28/cd3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel) - Лимфом, мантел-клетка - Антинеопластични средства - mantle cell lymphomatecartus is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl) after two or more lines of systemic therapy including a bruton’s tyrosine kinase (btk) inhibitor. acute lymphoblastic leukaemiatecartus is indicated for the treatment of adult patients 26 years of age and above with relapsed or refractory b-cell precursor acute lymphoblastic leukaemia (all).

Evrópusambandið - búlgarska - EMA (European Medicines Agency)

pierre fabre medicament - tabelecleucel - lymphoproliferative disorders - ebvallo is indicated as monotherapy for treatment of adult and paediatric patients 2 years of age and older with relapsed or refractory epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) who have received at least one prior therapy. for solid organ transplant patients, prior therapy includes chemotherapy unless chemotherapy is inappropriate.